MSX Opens Pre-IPO Subscriptions for Neuralink and Anduril, Expanding Tokenized Private Market Access

MSX, a real-world asset (RWA) platform, has launched its third pre-IPO investment offering, giving eligible users access to tokenized shares of Neuralink and Anduril. The subscription window runs from Aug. 31 to Sept. 6, with allocations tied to assets held on the platform.

Offering Details and Valuation

According to MSX, Neuralink is offered at a $42 billion valuation, with a total offering size of $3 million and a subscription price of 219 $USDT per token. Anduril, meanwhile, is priced at a $115 billion valuation, also with a $3 million offering size, at 130 $USDT per token.

These figures reflect the current private market valuations of both companies, which have seen significant investor interest due to their roles in neurotechnology and defense technology, respectively. Neuralink, founded by Elon Musk, focuses on brain-computer interfaces, while Anduril specializes in autonomous defense systems.

How MSX Tokenization Works

MSX operates as a platform that tokenizes private company shares, allowing retail and institutional investors to gain exposure to pre-IPO companies through blockchain-based assets. Users must hold assets on the platform to participate, with allocation limits determined by their holdings. The subscription process is conducted in $USDT, a stablecoin pegged to the US dollar, providing a familiar medium for crypto-native investors.

This offering marks MSX’s third such initiative, following previous pre-IPO rounds. The platform’s approach aims to bridge traditional private equity with decentralized finance, though it also introduces regulatory and liquidity considerations that investors should weigh.

Market Context and Implications

The move comes amid growing interest in RWA tokenization, as platforms seek to democratize access to high-growth private companies. However, investors should note that tokenized pre-IPO assets may have limited secondary market liquidity and are subject to regulatory uncertainties. The valuations cited are based on the latest funding rounds, but private market valuations can fluctuate.

For MSX users, this offering provides a rare opportunity to participate in the growth stories of Neuralink and Anduril, but it also carries risks inherent to early-stage investments. The platform’s allocation model ensures that larger holders have priority, which could influence participation strategies.

Conclusion

MSX’s third pre-IPO offering for Neuralink and Anduril reflects the expanding intersection of blockchain and private markets. While the opportunity is notable, potential investors should conduct thorough due diligence and consider the platform’s terms, valuation accuracy, and the broader regulatory landscape. As RWA platforms evolve, they could reshape how individuals access private equity, but prudence remains essential.

FAQs

Q1: What is MSX?
MSX is a real-world asset (RWA) platform that tokenizes private company shares, allowing users to invest in pre-IPO companies via blockchain-based tokens.

Q2: How can I participate in the subscription?
Users must hold assets on the MSX platform and adhere to allocation limits. The subscription is conducted in $USDT, with a window from Aug. 31 to Sept. 6.

Q3: What are the risks of investing in tokenized pre-IPO shares?
Risks include limited liquidity, potential regulatory changes, valuation volatility, and the inherent uncertainty of early-stage companies. Investors should assess these factors before participating.